Umamaheswara Maruvada, MD
Psychiatry · Corpus Christi, TXNPI 1053300103
Payments from drug & device makers
Across 294 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$625
- Sunovion Pharmaceuticals Inc.$576
- Supernus Pharmaceuticals, Inc.$573
- Neurocrine Biosciences, Inc.$434
- Johnson & Johnson$430
- plus $2K from 10 others
What the payments were for
- Food & beverage$5,352100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 63 | $1,166 |
| Teva Pharmaceuticals USA, Inc. | 25 | $625 |
| Sunovion Pharmaceuticals Inc. | 46 | $576 |
| Supernus Pharmaceuticals, Inc. | 29 | $573 |
| Neurocrine Biosciences, Inc. | 19 | $434 |
| Johnson & Johnson | 13 | $430 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $408 |
| Otsuka America Pharmaceutical, Inc. | 21 | $407 |
| AbbVie(2 entities) | 17 | $266 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $149 |
| Vanda Pharmaceuticals Inc. | 7 | $108 |
| Neos Therapeutics, LP | 4 | $73 |
| Ironshore Pharmaceuticals Inc. | 4 | $65 |
| Merck | 3 | $44 |
| Indivior Inc. | 1 | $16 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$892
- ARISTADA$407
- INVEGA SUSTENNA$207
- UZEDY$122
- INGREZZA$111
- AUSTEDO$105
- ARISTADA INITIO$102
How this compares
$5,352 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 59 | $163,789 |
| IngrezzaValbenazine Tosylate | 16 | $129,003 |
| AustedoDeutetrabenazine | 19 | $113,269 |
| Invega TrinzaPaliperidone Palmitate | 13 | $108,043 |
| Invega SustennaPaliperidone Palmitate | 34 | $94,605 |
| RexultiBrexpiprazole | 14 | $28,046 |
| AristadaAripiprazole Lauroxil | 13 | $23,374 |
| VraylarCariprazine Hcl | 13 | $19,242 |
| Lurasidone Hcl | 39 | $15,300 |
| TrintellixVortioxetine Hydrobromide | 16 | $11,578 |
| Aripiprazole | 86 | $4,947 |
| Buspirone Hcl | 215 | $3,930 |
| Bupropion XlBupropion Hcl | 136 | $3,222 |
| Hydroxyzine Hcl | 97 | $3,192 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 46 | $2,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $430 | $202,64847 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $407 | $191,83573 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $434 | $129,00316 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $625 | $113,26919 claims |
| Alkermes, Inc.Aristada | $1,166 | $23,37413 claims |
| AbbVieVraylar | $266 | $19,24213 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $149 | $11,57816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Corpus Christi
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
- Sejal MehtaPlano$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.